New Ray Medicine International Holding Full Year 2024 Earnings: HK$0.019 loss per share (vs HK$0.013 loss in FY 2023)

Simply Wall St

March 27, 2025

New Ray Medicine International Holding (HKG:6108) Full Year 2024 Results

Key Financial Results

Revenue: HK$93.9m (up 87% from FY 2023).
Net loss: HK$31.0m (loss widened by 40% from FY 2023).
HK$0.019 loss per share (further deteriorated from HK$0.013 loss in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

earnings-and-revenue-history — SEHK:6108 Earnings and Revenue History March 27th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

New Ray Medicine International Holding shares are up 9.5% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for New Ray Medicine International Holding (1 is concerning!) that you should be aware of.

If you're looking to trade New Ray Medicine International Holding, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if New Ray Medicine International Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.